TY - JOUR
T1 - Clinical neurotransplantation protocol for Huntington's and Parkinson's disease
AU - Lopez, William Omar Contreras
AU - Nikkhah, Guido
AU - Kahlert, Ulf D.
AU - Maciaczyk, Donata
AU - Bogiel, Tomasz
AU - Moellers, Sven
AU - Schültke, Elisabeth
AU - Döbrössy, Máté
AU - Maciaczyk, Jaroslaw
PY - 2013
Y1 - 2013
N2 - Purpose: The concept of transplantation of neuronal cells to treat Huntington's and Parkinson's diseases is based on the proven principle that dopaminergic and GABA-ergic progenitor neurons (from the human developing ventral mesencephalon and whole ganglionic eminence) can survive, differentiate and functionally integrate into an allogenic host brain. However, several donor and host-specific variables play a major role in the safety and outcome of this procedure. In this paper, we seek to summarize an updated neural transplantation protocol, based on our institutional experience and many years of collaboration with other neurotransplantation centers. Methods: We present a detailed clinical neurotransplantation protocol for Parkinson's (PD) and Huntington's (HD) diseases with special emphasis in understanding the anatomical relationships of the human fetal tissue that are relevant for selection of the desired cell populations. Results: Two detailed step-wise neurotransplantation protocols are presented, outlining strategies facilitating the avoidance of possible procedure-related complications. Conclusions: In this paper we delineated some crucial technical factors enabling the execution of a safe and effective neural transplantation. The protocols presented here might contribute to further development of the experimental clinical neurotransplantation towards a routine therapeutic procedure.
AB - Purpose: The concept of transplantation of neuronal cells to treat Huntington's and Parkinson's diseases is based on the proven principle that dopaminergic and GABA-ergic progenitor neurons (from the human developing ventral mesencephalon and whole ganglionic eminence) can survive, differentiate and functionally integrate into an allogenic host brain. However, several donor and host-specific variables play a major role in the safety and outcome of this procedure. In this paper, we seek to summarize an updated neural transplantation protocol, based on our institutional experience and many years of collaboration with other neurotransplantation centers. Methods: We present a detailed clinical neurotransplantation protocol for Parkinson's (PD) and Huntington's (HD) diseases with special emphasis in understanding the anatomical relationships of the human fetal tissue that are relevant for selection of the desired cell populations. Results: Two detailed step-wise neurotransplantation protocols are presented, outlining strategies facilitating the avoidance of possible procedure-related complications. Conclusions: In this paper we delineated some crucial technical factors enabling the execution of a safe and effective neural transplantation. The protocols presented here might contribute to further development of the experimental clinical neurotransplantation towards a routine therapeutic procedure.
KW - Human fetal neural precursor cells (hFNPCs)
KW - Huntington's disease (HD)
KW - Parkinson's disease (PD)
KW - good clinical practice (GCP)
KW - neural stem cells (NSC)
KW - neural transplantation
KW - substantia nigra (SN)
KW - ventral mesencephalon (VM)
KW - whole ganglionic eminence (WGE)
UR - http://www.scopus.com/inward/record.url?scp=84883870483&partnerID=8YFLogxK
U2 - 10.3233/RNN-130317
DO - 10.3233/RNN-130317
M3 - Artículo Científico
C2 - 23777636
AN - SCOPUS:84883870483
SN - 0922-6028
VL - 31
SP - 579
EP - 595
JO - Restorative Neurology and Neuroscience
JF - Restorative Neurology and Neuroscience
IS - 5
ER -